Revolution Medicines said its Phase 3 study of daraxonrasib in advanced pancreatic adenocarcinoma produced a median survival of 13.2 months versus 6.7 months with standard chemotherapy, delivering a survival benefit that the company plans to use for an FDA approval application. The Readout Loud transcript with trial investigator Paul Oberstein (NYU Langone’s Perlmutter Cancer Center) emphasized why the KRAS-targeting effort has become central to current pancreatic cancer drug development, after earlier KRAS strategies showed limited durability. Revolution also framed the dataset as potentially enabling faster regulatory review, though no submission date was provided in the reporting.